BiotechTube
Evexta Bio

Evexta Bio

Paris, France· Est.
evextabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Evexta Bio is a Paris-based, clinical-stage biotechnology company founded in 2019, developing novel oncology therapeutics. Its lead asset, rupitasertib, is a first-in-class oral dual inhibitor of the PAM pathway (targeting S6K and AKT1/3) aimed at overcoming treatment resistance in advanced breast cancer, currently in Phase 1. The second program, EVX020, is a first-in-class KIF20A inhibitor being developed as an antibody-drug conjugate (ADC) payload for hematological and solid tumors. The company is backed by Truffle Capital and has established key partnerships with institutions like CNRS and Merck KGaA.

Oncology

Technology Platform

Targeted asset strategy focusing on novel nodes in cancer pathways, including a double-node PAM pathway inhibitor and a first-in-class KIF20A inhibitor for ADC payloads.

Funding History

2
Total raised:$15M
Series A$12M
Seed$3M

Opportunities

The primary opportunity lies in addressing the large unmet need of therapy resistance in ER+ HER2- advanced breast cancer with rupitasertib's novel dual mechanism.
Additionally, the EVX020 program offers a first-in-class ADC payload that could target a broad range of hematological and solid tumors, entering the high-growth ADC market with a differentiated approach.

Risk Factors

Key risks include clinical failure of novel mechanisms, intense competition in oncology from larger players, and reliance on future fundraising to advance programs given its pre-revenue status.
The multi-year timeline to pivotal data (Phase 1b trial start in 2026) also introduces execution and market risk.

Competitive Landscape

Evexta Bio competes in the crowded breast cancer therapeutics market against numerous PI3K/AKT/mTOR pathway inhibitors and next-generation SERDs. Its differentiation hinges on rupitasertib's unique safety/efficacy profile. In the ADC space, EVX020 will compete against established payload technologies and a pipeline of novel agents from major pharmaceutical companies.

More companies in Biologics / Biosimilars →More companies in France →